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Abstract
Many studies have shown that a motif of 11 consecutive arginines (11R) is one of the most
effective protein transduction domains (PTD) for introducing proteins into the cell membrane. By
conjugating this “11R”, all sorts of proteins can effectively and harmlessly be transferred into any
kind of cell. We therefore examined the transduction efficiency of 11R in cerebral arteries and
obtained results showing that 11R fused enhanced green fluorescent protein (11R-EGFP) imme-
diately and effectively penetrated all layers of the rat basilar artery (BA), especially the tunica
media. This method provides a revolutionary approach to cerebral arteries and ours is the first
study to demonstrate the successful transductionof a PTD fused protein into the cerebral arter-
ies. In this review, we present an outline of our studies and other key studies related to cerebral
vasospasm and 11R, problems to be overcome, and predictions regarding future use of the 11R
protein transduction method for cerebral vasospasm (CV).
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Many studies have shown that a motif of 11 consecutive arginines (11R) is one of the most eﬀective 
protein transduction domains (PTD) for introducing proteins into the cell membrane.  By conjugating 
this “11R”,  all sorts of proteins can eﬀectively and harmlessly be transferred into any kind of cell.  We 
therefore examined the transduction eﬃciency of 11R in cerebral arteries and obtained results showing 
that 11R fused enhanced green ﬂuorescent protein (11R-EGFP) immediately and eﬀectively penetrated 
all layers of the rat basilar artery (BA),  especially the tunica media.  This method provides a revolu-
tionary approach to cerebral arteries and ours is the ﬁrst study to demonstrate the successful trans-
duction of a PTD fused protein into the cerebral arteries.  In this review,  we present an outline of our 
studies and other key studies related to cerebral vasospasm and 11R,  problems to be overcome,  and 
predictions regarding future use of the 11R protein transduction method for cerebral vasospasm (CV).
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erebral vasospasm with delayed ischemic neuro-
logical deﬁcit occurs in 30ｵ to 70ｵ of patients 
with aneurysmal subarachnoid hemorrhage (SAH) [1].  
Despite studies demonstrating promising therapeutic 
approaches such as endothelin receptor antagonists 
[2,  3] calcium antagonists,  or sodium nitroprusside 
[4,  5],  cerebral vasospasm remains a major cause of 
morbidity and mortality and an important cause of 
cerebral ischemia and stroke after SAH [6ﾝ8].  
Clearly,  to improve clinical outcomes for more 
patients with SAH,  the development of eﬀective 
therapies is required.
　 Gene therapy is a promising strategy and is cur-
rently being studied for a variety of cerebrovascular 
diseases,  including cerebral vasospasm after suba-
rachnoid hemorrhage (SAH).  However,  this therapy 
must go through a multistep process for therapeutic 
proteins to be expressed,  expression has been 
observed only in adventitia overlying cerebral vessels,  
and its eﬃcacy of transduction is not high enough [9ﾝ
11].  Moreover,  in general,  virus-mediated gene 
therapy has some critical limitations due to inﬂamma-
tory response,  the cytotoxicity of viruses,  and random 
integration of viral vector DNA into the host chromo-
somes [12].
　 Recent studies have shown that by conjugating 10ﾝ
20 amino acid peptides,  referred to as a “protein 
transduction domain (PTD)”,  several proteins can be 
transduced directly,  harmlessly and eﬀectively into all 
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kinds of cells.  This method is called “protein ther-
apy” (Fig.  1).  Regarding PTD in this protein therapy,  
Matsushita et al.  have developed a novel PTD with 11 
sequential arginine arrangements,  that is,  “11R”.  
They proved that 11R is highly eﬃcient in delivering 
proteins directly into neuronal cells without toxicity 
[13].  Moreover,  in cerebral arteries,  we found that 
11R-fused enhanced green fluorescent protein 
(11R-EGFP) immediately,  selectively and eﬀectively 
penetrates all layers of the rat basilar artery (BA),  
especially the tunica media (smooth muscle layer) 
[14].  In this review,  these ﬁndings with regard to 
11R protein transduction method are described.
Gene Therapy for Cerebral Vasospasm
　 For therapy for cerebral vasospasm,  viral-medi-
ated gene transfer is an attractive intervention 
because viral vectors have the natural ability to enter 
cells and direct the expression of transgenes by 
infected host cells [15ﾝ17].  Actually,  to date,  there 
have been several experimental studies of gene trans-
fer by adenovirus vector into cerebral vessels [9,  18,  
19].
　 Impaired endothelium-dependent vasorelaxation is 
thought to be one of the most important mechanisms of 
vasospasm after SAH [20,  21].  This mechanism was 
examined by Onoue et al.  They proved that in vivo gene 
transfer of endothelial NOS improves NO-mediated 
relaxation in vitro of basilar arteries after experimen-
tal SAH [9].  Khurana et al.  have also reported par-
tial attenuation of constriction of the basilar artery in 
vivo after SAH,  using gene transfer of endothelial 
NOS before SAH [15].
　 Kajita et al.  and Shishido et al.  have reported that 
superoxide may contribute to cerebral vasospasm,  and 
superoxide dismutase (SOD) is a candidate for the 
prevention of vasospasm after SAH [22,  23].  
Transgenic mice that overexpress CuZnSOD or 
ECSOD have improved cerebral vasoconstriction after 
experimental SAH [18,  24].  Nakane et al.  and 
Watanabe et al.  have demonstrated a partial protec-
tive eﬀect against vasospasm after SAH by injection 
into CSF of an adenovirus that expresses ECSOD 
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Fig. 1　 Protein therapy.  By conjugating 10-20 amino acid peptides, therapeutic proteins can be transduced directly, harmlessly and 
eﬃciently into any kind of cell.
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[19,  25].  Antisense preproendothelin-1 oligodeoxy-
nucleotide,  which reduces production of endothelin 
peptide,  attenuates vasospasm after SAH following 
intracisternal injection of the antisense alone [26] or 
together with tissue plasminogen activator to dissolve 
the subarachnoid thrombin [27].
　 Calcitonin gene-related peptide (CGRP) opens 
potassium channels,  hyperpolarizes arterial muscle,  
and dilates arteries.  This peptide is therefore an 
extremely potent cerebral vasodilator,  which may 
prove useful for the prevention of vasospasm after 
SAH [28].  After SAH,  CGRP is depleted from 
nerves to cerebral arteries [29,  30].  Nozaki et al.  
have also reported that intracisternal or systemic 
administration of exogenous CGRP increases the 
cerebral arterial diameter in vivo after experimental 
SAH [31,  32].  Toyoda et al.  have hypothesized that 
intracranial overexpression of CGRP for longer peri-
ods by a gene transfer technique might be eﬀective for 
the prevention of vasospasm after SAH and proved 
that a recombinant adenoviral vector encoding prepro-
CGRP modulates cerebrovascular tone after intracis-
ternal gene transfer [17].  In addition,  treatment of 
rabbits with this vector after SAH has been found to 
prevent vasospasm [33].  The eﬀectiveness of this 
strategy has also been demonstrated using a dog model 
of SAH [10].
　 Cerebral vasospasm after SAH may also be related 
in part to inﬂammatory vasculitis [34,  35],  and inhi-
bition of inﬂammation by gene transfer appears to 
reduce vasocontraction [36].  The transcription factor 
NFkB plays an essential role in the activation of 
inﬂammatory cytokines and adhesion molecules.  
Intracisternal administration of a decoy oligodeoxy-
nucleotide of NFkB has been reported to be useful for 
the prevention of vasospasm [36].
　 These virus-mediated gene therapies have,  how-
ever,  signiﬁcant safety problems such as inﬂammatory 
response,  viral toxicity,  and random integration of the 
viral vectorʼs DNA into the host chromosomes [12,  
37,  38].  Moreover,  by transcisternal application,  
the eﬃciency of adenoviral vector-mediated gene 
transfer is not suﬃcient for clinical use because genes 
can be transferred only into the adventitia overlying 
cerebral vessels [9ﾝ11,  39].  Liposomes are surely 
able to deliver exogenous genes with minimal toxicity 
in vivo [36,  40,  41],  but the eﬃciency of gene trans-
duction is at present worse than that of virus-medi-
ated gene transfer [12].
History of the PTD Method
　 Green et al.  and Frankel et al.  have proven that the 
TAT protein,  a transcription activator protein of 
HIV,  can penetrate a cell through the membrane bar-
rier [42,  43].  This result indicates that the TAT 
protein maintains physiological activity after transduc-
tion into the cell.  The transduction activity in the 
TAT protein was attributed to its N-terminal 
11-amino acid domain sequence.  The sequence was 
named the PTD (Protein Transduction Domain).  
Diﬀerent PTDs have been identiﬁed in Antennapedia 
protein (Antp) from the homeotic gene product and 
HSV VP22 from Human Stomatitis Virus-1 [44,  
45].
　 Fawell et al.  have reported the delivery of β
-galactosidase,  horseradish peroxidase,  RNase,  and 
a protein toxin into cells in vivo by a chemically cross-
linked TAT peptide composed of a 36-amino acid 
sequence that included the 11-amino acid TAT-PTD 
sequence [46].  Dowdy and his colleagues have 
reported that TAT-PTD can deliver β-galactosidase 
into diverse organs in vivo,  including liver,  kidney,  
lung,  heart muscle,  and spleen by a way of intraperi-
toneal injection [47].  They showed that the brain is 
also a good target of delivery.  Cao et al.  and Asoh et 
al.  have shown that intraperitoneal in vivo application 
of anti-apotic Bcl-xL protein or its constitutively 
active form fused with TAT-PTD can protect neurons 
from ischemia-induced apoptosis [48,  49].
　 These studies with the TAT protein transduction 
system have demonstrated 3 important points: First,  
not only a small peptide but also high-molecular weight 
proteins can be delivered into cells through the mem-
brane barrier by TAT-PTD.  Second,  the delivered 
proteins are kept physiologically active as enzymes or 
an anti-apoptotic protein.  Third,  TAT-PTD can go 
through the blood brain barrier under some experi-
mental conditions.  With these features,  the TAT 
protein transduction system can be expected to provide 
a completely novel tool for the study of protein func-
tion and eventually a new drug-delivery method for 
clinical application.  Although the TAT protein trans-
duction system overcame the problems of virus vector 
methods such as an immune reaction,  it still showed 
its own limitations such as inhibitory eﬀects on neu-
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ronal function and a relatively low transduction eﬃ-
cacy.  Therefore,  for the purpose of clinical use,  it is 
necessary and critical to develop a new protein deliv-
ery system with a higher transduction eﬃcacy and 
non-toxicity to normal tissues.
　 The protein transduction domain in the TAT pro-
tein includes 6 arginines and 2 lysines.  Based on the 
amino acid sequence of the PTD in TAT and other 
proteins [44,  50,  51],  Matsushita et al.  have specu-
lated that arginine is the most important factor for 
membrane penetration.  They therefore constructed a 
bacteria expression vector that has 7 arginines (7R),  
9 arginines (9R),  or 11 arginines (11R),  followed by 
EGFP.  Recombinant proteins were puriﬁed under 
denatured conditions and dialyzed against PBS as 
described previously [47].  To analyze the transduc-
tion ability of arginine-based PTD-EGFP proteins,  
Cos-7 cells were incubated with the protein and ana-
lyzed by confocal laser microscopy.  Without the PTD 
domain,  EGFP showed no green ﬂuorescent signal in 
the cells.  The original TAT-EGFP showed the signal 
in both the cytoplasm and the nucleus of Cos-7 cells.  
In contrast,  the 11R-EGFP showed a much stronger 
signal than the original TAT-EGFP in all regions of 
the cells.  Incubation with 11R-EGFP,  9R-EGFP,  
and 7R-EGFP demonstrated that the arginine length 
is a critical factor in determining the transduction 
eﬃcacy into culture cells and that 11R is the most 
eﬃcient transduction domain sequence.  Futaki et al.,  
Wender et al.,  and Rothbard et al.  have also reported 
that polyarginines and arginine-rich peptides are good 
tools for protein transduction [52ﾝ55].  Therefore,  
we used “11R” as PTD in our recent study.
The Mechanisms of Protein Transduction of 
PTD-fusion Proteins
　 The mechanisms of protein transduction of PTD-
fusion proteins into cells have been investigated in 
many previous studies.  Early mechanistic studies 
showed that TAT-mediated transduction occurs 
through a rapid temperature- and energy-independent 
process,  suggesting direct penetration across the lipid 
bilayer [41,  46].  Wadia et al.  [56] have shown that 
TAT fusion proteins are rapidly internalized by lipid 
raft-dependent macropinocytosis,  and that most of the 
internalized proteins are entrapped in macropino-
somes.  A recent study showed that 11R PTD fused 
with the inﬂuenza virus hemagglutinin-2 protein,  
which has the beneﬁcial aspect of disrupting only 
macropinosomes but no other types of vesicles,  mark-
edly enhances the eﬀects of fusion proteins.  The 
authors showed that the linking of hemagglutinin-2 
protein with 11R-p53 protein induces delivery into the 
nucleus of glioma cells and strongly enhances the 
anticancer eﬀect of p53,  providing that 11R fusion 
proteins function by the same mechanism of internal-
ization into cells as TAT fusion proteins [57].
Advantages of the 11R Protein Transduction 
Method for Cerebral Vasospasm
　 In a recent study,  we found that intracisternal 
protein transduction using an 11R-fusion protein 
selectively delivers this protein into cerebral vessels,  
and the delivered protein is especially transduced into 
the tunica media (smooth muscle layer) of the BA,  
even when it has been exposed to SAH.  These ﬁnd-
ings suggest that this protein transduction method may 
be a more eﬀective therapeutic method for treatment 
of cerebral arteries than viral vector-mediated gene 
transduction therapy.  The high expression of 11R- 
EGFP was maintained when the BAs continued to 
incubate with 11R-EGFP for 12h ex vivo.  At the same 
time,  the elevated expression level of 11R-EGFP was 
gradually decreased during 12h in blood vessels with 
only a single injection of 11R-EGFP in vivo.  These 
results indicated that repeated administration of 
11R-fused proteins might be needed to maintain a 
desired therapeutic eﬀect.  It has also been claimed 
that protein therapy is superior to viral vector-medi-
ated gene therapy in terms of inﬂammatory response.  
Previous studies have indicated that PTD-fused p53 
is not toxic and does not aﬀect normal cells,  whereas 
adenovirus-p53 signiﬁcantly induces detrimental 
eﬀects in normal cells [58,  59].  We also found in the 
present study that there was no immunoreactivity after 
injection with 11R-EGFP.  Moreover,  Schwarze et al.  
[60] examined the potential immune responses and 
toxicity associated with long-term transduction of PTD 
fusion proteins and noted that injection of a mouse 
with 1mg of a TAT PTD fusion protein per kilogram 
of body weight each day for 14 consecutive days pro-
duced no signs of gross neurological problems or sys-
temic distress.  However,  for blood vessels,  these 
issues related to long-term transduction of proteins 
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have not yet been elucidated in detail.  Therefore,  a 
protein therapy that will reliably transduce stable 
proteins into blood vessels must be developed.  Before 
initiating clinical trials of protein transduction therapy 
for treatment of cerebral arteries,  the noted remain-
ing challenges of protein therapy must be overcome.
Future Perspectives of the 11R Protein 
Transduction Method for Cerebral Arteries
　 Our recent report shows that 11R-EGFP could be 
transduced eﬀectively into all layers of rat cerebral 
arteries at least 2h after injection of the protein.  
However,  the expression in cerebral arteries was not 
maintained for a long time with only a single injection 
of the protein.  These characteristics of protein ther-
apy may be suitable for acute but transient cerebro-
vascular disorders such as cerebral vasospasm after 
SAH or stroke rather than chronic medical conditions 
like the pathology of cancer.
　 Moreover,  by intrathecal administration,  11R- 
EGFP was not translocated into the brain paren-
chyma,  but selectively into the rat BAs.  This ﬁnding 
shows that this 11R-based transcisternal protein 
transduction method may be an immediately eﬀective 
and highly selective treatment for cerebral arteries.  
This method may therefore be applied not only to 
cerebral vasospasm,  but also to other cerebrovascular 
diseases such as arteriosclerosis.
　 Interestingly,  all kinds of proteins,  peptides,  and 
therapeutic drugs can be transduced into cells by 
protein therapy [60ﾝ62].  We will therefore need to 
examine whether 11R-fused vasoactive proteins such 
as endothelial nitric oxide synthase or calcitonin gene-
related peptide are also eﬃciently delivered into 
cerebral arteries and have contractile or relaxant 
responses to cerebral arteries in the coming years.
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